624 related articles for article (PubMed ID: 19747996)
1. Antibiotic resistance free plasmid DNA expressing LACK protein leads towards a protective Th1 response against Leishmania infantum infection.
Ramos I; Alonso A; Peris A; Marcen JM; Abengozar MA; Alcolea PJ; Castillo JA; Larraga V
Vaccine; 2009 Nov; 27(48):6695-703. PubMed ID: 19747996
[TBL] [Abstract][Full Text] [Related]
2. Heterologous prime-boost vaccination with a non-replicative vaccinia recombinant vector expressing LACK confers protection against canine visceral leishmaniasis with a predominant Th1-specific immune response.
Ramos I; Alonso A; Marcen JM; Peris A; Castillo JA; Colmenares M; Larraga V
Vaccine; 2008 Jan; 26(3):333-44. PubMed ID: 18093705
[TBL] [Abstract][Full Text] [Related]
3. Vaccination with plasmid DNA encoding KMPII, TRYP, LACK and GP63 does not protect dogs against Leishmania infantum experimental challenge.
Rodríguez-Cortés A; Ojeda A; López-Fuertes L; Timón M; Altet L; Solano-Gallego L; Sánchez-Robert E; Francino O; Alberola J
Vaccine; 2007 Nov; 25(46):7962-71. PubMed ID: 17942199
[TBL] [Abstract][Full Text] [Related]
4. Long-lasting protection against canine visceral leishmaniasis using the LiESAp-MDP vaccine in endemic areas of France: double-blind randomised efficacy field trial.
Lemesre JL; Holzmuller P; Gonçalves RB; Bourdoiseau G; Hugnet C; Cavaleyra M; Papierok G
Vaccine; 2007 May; 25(21):4223-34. PubMed ID: 17395339
[TBL] [Abstract][Full Text] [Related]
5. Immunogenicity of HSP-70, KMP-11 and PFR-2 leishmanial antigens in the experimental model of canine visceral leishmaniasis.
Carrillo E; Crusat M; Nieto J; Chicharro C; Thomas Mdel C; Martínez E; Valladares B; Cañavate C; Requena JM; López MC; Alvar J; Moreno J
Vaccine; 2008 Mar; 26(15):1902-11. PubMed ID: 18321614
[TBL] [Abstract][Full Text] [Related]
6. Leishmania donovani p36(LACK) DNA vaccine is highly immunogenic but not protective against experimental visceral leishmaniasis.
Melby PC; Yang J; Zhao W; Perez LE; Cheng J
Infect Immun; 2001 Aug; 69(8):4719-25. PubMed ID: 11447143
[TBL] [Abstract][Full Text] [Related]
7. Antigenicity of
Fernández L; Carrillo E; Sánchez-Sampedro L; Sánchez C; Ibarra-Meneses AV; Jimenez MA; Almeida VDA; Esteban M; Moreno J
Front Immunol; 2018; 9():843. PubMed ID: 29740446
[No Abstract] [Full Text] [Related]
8. The chimerical multi-component Q protein from Leishmania in the absence of adjuvant protects dogs against an experimental Leishmania infantum infection.
Carcelén J; Iniesta V; Fernández-Cotrina J; Serrano F; Parejo JC; Corraliza I; Gallardo-Soler A; Marañón F; Soto M; Alonso C; Gómez-Nieto C
Vaccine; 2009 Oct; 27(43):5964-73. PubMed ID: 19666153
[TBL] [Abstract][Full Text] [Related]
9. Protective vaccination against experimental canine visceral leishmaniasis using a combination of DNA and protein immunization with cysteine proteinases type I and II of L. infantum.
Rafati S; Nakhaee A; Taheri T; Taslimi Y; Darabi H; Eravani D; Sanos S; Kaye P; Taghikhani M; Jamshidi S; Rad MA
Vaccine; 2005 May; 23(28):3716-25. PubMed ID: 15882533
[TBL] [Abstract][Full Text] [Related]
10. Selection of appropriate serological tests to measure the incidence of natural Leishmania infantum infection during DNA/MVA prime/boost canine vaccine trials.
Carson C; Antoniou M; Christodoulou V; Messaritakis I; Quinnell RJ; Blackwell JM; Courtenay O
Vet Parasitol; 2009 Jun; 162(3-4):207-13. PubMed ID: 19386420
[TBL] [Abstract][Full Text] [Related]
11. Protection against experimental visceral leishmaniasis infection in dogs immunized with purified excreted secreted antigens of Leishmania infantum promastigotes.
Lemesre JL; Holzmuller P; Cavaleyra M; Gonçalves RB; Hottin G; Papierok G
Vaccine; 2005 Apr; 23(22):2825-40. PubMed ID: 15780731
[TBL] [Abstract][Full Text] [Related]
12. Vaccination of dogs with six different candidate leishmaniasis vaccines composed of a chimerical recombinant protein containing ribosomal and histone protein epitopes in combination with different adjuvants.
Poot J; Janssen LH; van Kasteren-Westerneng TJ; van der Heijden-Liefkens KH; Schijns VE; Heckeroth A
Vaccine; 2009 Jul; 27(33):4439-46. PubMed ID: 19500553
[TBL] [Abstract][Full Text] [Related]
13. Cysteine proteinase type III is protective against Leishmania infantum infection in BALB/c mice and highly antigenic in visceral leishmaniasis individuals.
Khoshgoo N; Zahedifard F; Azizi H; Taslimi Y; Alonso MJ; Rafati S
Vaccine; 2008 Oct; 26(46):5822-9. PubMed ID: 18804512
[TBL] [Abstract][Full Text] [Related]
14. Immunogenicity of a multicomponent DNA vaccine against visceral leishmaniasis in dogs.
Saldarriaga OA; Travi BL; Park W; Perez LE; Melby PC
Vaccine; 2006 Mar; 24(11):1928-40. PubMed ID: 16310897
[TBL] [Abstract][Full Text] [Related]
15. Recombinant Leishmania tarentolae expressing the A2 virulence gene as a novel candidate vaccine against visceral leishmaniasis.
Mizbani A; Taheri T; Zahedifard F; Taslimi Y; Azizi H; Azadmanesh K; Papadopoulou B; Rafati S
Vaccine; 2009 Dec; 28(1):53-62. PubMed ID: 19818721
[TBL] [Abstract][Full Text] [Related]
16. Prime-boost vaccination using cysteine proteinases type I and II of Leishmania infantum confers protective immunity in murine visceral leishmaniasis.
Rafati S; Zahedifard F; Nazgouee F
Vaccine; 2006 Mar; 24(12):2169-75. PubMed ID: 16325969
[TBL] [Abstract][Full Text] [Related]
17. Canine Leishmania vaccines: still a long way to go.
Gradoni L
Vet Parasitol; 2015 Feb; 208(1-2):94-100. PubMed ID: 25620293
[TBL] [Abstract][Full Text] [Related]
18. The antibiotic resistance-free mammalian expression plasmid vector pPAL for development of third generation vaccines.
Alcolea PJ; Alonso A; Larraga V
Plasmid; 2019 Jan; 101():35-42. PubMed ID: 30529129
[TBL] [Abstract][Full Text] [Related]
19. Recombinant Forms of Leishmania amazonensis Excreted/Secreted Promastigote Surface Antigen (PSA) Induce Protective Immune Responses in Dogs.
Petitdidier E; Pagniez J; Papierok G; Vincendeau P; Lemesre JL; Bras-Gonçalves R
PLoS Negl Trop Dis; 2016 May; 10(5):e0004614. PubMed ID: 27223609
[TBL] [Abstract][Full Text] [Related]
20. Failure of a multi-subunit recombinant leishmanial vaccine (MML) to protect dogs from Leishmania infantum infection and to prevent disease progression in infected animals.
Gradoni L; Foglia Manzillo V; Pagano A; Piantedosi D; De Luna R; Gramiccia M; Scalone A; Di Muccio T; Oliva G
Vaccine; 2005 Nov; 23(45):5245-51. PubMed ID: 16054272
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
